Induction of anti-tumor immunity by vaccination with dendritic cells pulsed with anti-CD44 IgG opsonized tumor cells
dc.contributor.author | Pilon-Thomas, Shari | en_US |
dc.contributor.author | Verhaegen, Monique E. | en_US |
dc.contributor.author | Kuhn, Lisa | en_US |
dc.contributor.author | Riker, Adam I. | en_US |
dc.contributor.author | Mulé, James J. | en_US |
dc.date.accessioned | 2006-09-11T16:33:29Z | |
dc.date.available | 2006-09-11T16:33:29Z | |
dc.date.issued | 2005-11-29 | en_US |
dc.identifier.citation | Pilon-Thomas, Shari; Verhaegen, Monique; Kuhn, Lisa; Riker, Adam; Mulé, James J; (2005). "Induction of anti-tumor immunity by vaccination with dendritic cells pulsed with anti-CD44 IgG opsonized tumor cells." Cancer Immunology, Immunotherapy (): 1-9. <http://hdl.handle.net/2027.42/45862> | en_US |
dc.identifier.issn | 0340-7004 | en_US |
dc.identifier.issn | 1432-0851 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/45862 | |
dc.description.abstract | Due to the pivotal role that dendritic cells (DC) play in eliciting and maintaining functional anti-tumor T cell responses, these APC have been exploited against tumors. DC express several receptors for the Fc portion of IgG (Fcγ receptors) that mediate the internalization of antigen-IgG complexes and promote efficient MHC class I and II restricted antigen presentation. In this study, the efficacy of vaccination with DC pulsed with apoptotic B16 melanoma cells opsonized with an anti-CD44 IgG (B16-CD44) was explored. Immature bone marrow derived DC grown in vitro with IL-4 and GM-CSF were pulsed with B16-CD44. After 48 h of pulsing, maturation of DC was demonstrated by production of IL-12 and upregulation of CD80 and CD40 expression. To test the efficacy of vaccination with DC+B16-CD44, mice were vaccinated subcutaneously Lymphocytes from mice vaccinated with DC+B16-CD44 produced IFN-γ in response to B16 melanoma lysates as well as an MHC class I restricted B16 melanoma-associated peptide, indicating B16 specific CD8 T cell activation. Upon challenge with viable B16 cells, all mice vaccinated with DC alone developed tumor compared to 40% of mice vaccinated with DC+B16-CD44; 60% of the latter mice remained tumor free for at least 8 months. In addition, established lung tumors and distant metastases were significantly reduced in mice treated with DC+B16-CD44. Lastly, delayed growth of established subcutaneous tumors was induced by combination therapy with anti-CD44 antibodies followed by DC injection. This study demonstrates the efficacy of targeting tumor antigens to DC via Fcγ receptors. | en_US |
dc.format.extent | 376039 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Springer-Verlag | en_US |
dc.title | Induction of anti-tumor immunity by vaccination with dendritic cells pulsed with anti-CD44 IgG opsonized tumor cells | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Microbiology and Immunology | en_US |
dc.subject.hlbsecondlevel | Biological Chemistry | en_US |
dc.subject.hlbtoplevel | Science | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | University of Michigan Medical Center, Ann Arbor, MI, USA, | en_US |
dc.contributor.affiliationother | H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr., SRB-3 Room 23244, Tampa, FL, 33612, USA, | en_US |
dc.contributor.affiliationother | H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr., SRB-3 Room 23244, Tampa, FL, 33612, USA, | en_US |
dc.contributor.affiliationother | H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr., SRB-3 Room 23244, Tampa, FL, 33612, USA, | en_US |
dc.contributor.affiliationother | H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr., SRB-3 Room 23244, Tampa, FL, 33612, USA, | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/45862/1/262_2005_Article_104.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1007/s00262-005-0104-8 | en_US |
dc.identifier.source | Cancer Immunology, Immunotherapy | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.